CLYM vs NVCT: stock comparison and AI forecast
Climb Bio, Inc. (CLYM) and Nuvectis Pharma, Inc. (NVCT) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CLYM Climb Bio, Inc.
- Market Cap
- $591M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
NVCT Nuvectis Pharma, Inc.
- Market Cap
- $579M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- CLYM and NVCT have similar market capitalizations ($591M and $579M).
- NVCT carries 0.11 times debt per unit of equity, against 0.04 times for CLYM.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CLYM | NVCT |
|---|---|---|
| Market Cap | $591M | $579M |
| P/B Ratio | 2.59x | 4.57x |
| EPS | $-0.87 | $-1.90 |
| Book Value/Share | $3.97 | $3.89 |
Profitability & Margins
| Metric | CLYM | NVCT |
|---|---|---|
| ROE | -26.0% | -39.8% |
| ROA | -25.1% | -35.8% |
| ROIC | -29.2% | -41.2% |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | CLYM | NVCT |
|---|---|---|
| Current Ratio | 26.58x | 9.92x |
| D/E Ratio | 0.04x | 0.11x |
| Financial Leverage | 1.04x | 1.11x |
| Working Capital | $202M | $127M |
Cash Flow
| Metric | CLYM | NVCT |
|---|---|---|
| Operating Cash Flow | -$53M | -$40M |
Income Statement
| Metric | CLYM | NVCT |
|---|---|---|
| Operating Income | -$67M | -$52M |
| Net Income | -$59M | -$50M |
| R&D Expense | $44M | $41M |
Dividend & Shareholder Information
| Metric | CLYM | NVCT |
|---|---|---|
| Shares Outstanding | 57M | 33M |
| EPS Growth | -495.4% | – |
CLYM vs NVCT: stock comparison and AI forecast
Which is bigger, CLYM or NVCT?
CLYM and NVCT have similar market capitalizations ($591M and $579M).
Which one does Intratio's AI model rank higher, CLYM or NVCT?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.